VT-1598, an investigational tetrazole antifungal that selectively inhibits fungal CYP51, is in early-phase clinical development for the treatment of coccidioidomycosis.[58]Wiederhold NP, Shubitz LF, Najvar LK, et al. The novel fungal Cyp51 inhibitor VT-1598 is efficacious in experimental models of central nervous system coccidioidomycosis caused by coccidioides posadasii and coccidioides immitis. Antimicrob Agents Chemother. 2018 Apr;62(4):.
https://www.doi.org/10.1128/AAC.02258-17
http://www.ncbi.nlm.nih.gov/pubmed/29437615?tool=bestpractice.com
Oral administration improved survival and decreased fungal burden in mouse models.[58]Wiederhold NP, Shubitz LF, Najvar LK, et al. The novel fungal Cyp51 inhibitor VT-1598 is efficacious in experimental models of central nervous system coccidioidomycosis caused by coccidioides posadasii and coccidioides immitis. Antimicrob Agents Chemother. 2018 Apr;62(4):.
https://www.doi.org/10.1128/AAC.02258-17
http://www.ncbi.nlm.nih.gov/pubmed/29437615?tool=bestpractice.com